Marvell's Lumentum Deal: Two Downgrades, One Confirmed Outlook and a 2028 Waiting Game

Marvell Technology shares slipped another 3.4% today, extending a retreat that Reuters attributes to investor unease over dilution and the risks embedded in the company's planned acquisition of Lumentum. The stock-funded structure of the deal has become the prism through which everything else is now read — including a sales update that, on its own, would ordinarily have been taken as reassuring.

The transaction, agreed on Monday, is to be settled entirely in Marvell equity. Lumentum holders are set to receive 4,500 Marvell shares for each of their own, valuing the combination at an implied enterprise value of $115 billion. Existing Marvell shareholders are expected to own roughly 67% of the merged company. That arithmetic explains why dilution sits at the centre of the debate rather than at its edges.

Price Targets Cut, Conviction Split

Tuesday brought a wave of revisions from the sell side, though not a uniform verdict. TD Cowen downgraded the stock from Buy to Hold and slashed its target to $175 from $350, as reported by CNBC. Bank of America moved from Buy to Neutral and trimmed its target to $225 from $400. RBC Capital Markets took a different route: it cut its target to $250 from $425 but kept its Outperform rating intact.

The distinction matters. A lower target reflects a reduced valuation, not necessarily a changed recommendation, and RBC's decision to stay positive shows that the analyst community is not speaking with one voice on whether Marvell remains attractive once transaction risk is folded in. Investors would do well to separate the size of a target cut from the direction of the call.

The Operating Anchor Still Holds

Against that backdrop, Marvell's preliminary revenue disclosure offers the clearest counterweight. The company confirmed the midpoint of its prior guidance for the third quarter of fiscal 2027 and narrowed the expected range from ±5% to ±2%. No upgrade was issued — but the central expectation survived intact, and the tighter band limits the expected dispersion around it.

That is a stability signal, not an all-clear. A narrowed range says little about whether the Lumentum combination will prove economically worthwhile for today's holders, and it does nothing to address the share issuance that underpins the deal. Confirmed business expectations and freshly repriced transaction risk are two separate questions, and they deserve separate answers.

What Would Change the Narrative

A more favourable reading of Marvell does not require the merger to close first. It would be enough for the company to reinforce the reliability of its preliminary figures while concerns about the transaction lose some of their weight, allowing valuation to gravitate back toward operating performance. Confirmation alone, however, would not fully answer the dilution question.

The bar for that shift has risen. Both Tuesday's downgrades point in the same direction, and neither is merely a reaction to the share price — they target the deal itself, a factor that a tighter revenue band cannot resolve. Should dilution and completion risk keep gaining prominence, the sales update on its own is unlikely to sustain a durable turn in confidence.

Approvals Are the Next Hurdle

The concrete test on the transaction side is regulatory clearance. Marvell and Lumentum expect the deal to close in the first half of 2028, subject to the necessary approvals — agreed, in other words, but not yet completed.

Two separate tracks therefore deserve attention from here: hard operating results and progress on the conditions for closing. Only when both begin to undercut the sceptical case does the constructive scenario become convincing. Until then, the confirmed revenue outlook stands as an argument for stability — not as a release from the risks attached to the Lumentum transaction.